Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
VTRS Price Action
Last 7 days
1.7%
Last 30 days
11.3%
Last 90 days
-22.6%
Trailing 12 Months
-28.3%
VTRS Stock Price
VTRS RSI Chart
VTRS Valuation
VTRS Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
VTRS Fundamentals
VTRS Revenue
VTRS Earnings
VTRS Profitability
VTRS Investor Care
Revenue & Growth
Revenue Breakdown
As of: Dec 31, 2024
Developed Markets
| |||||||||||||||||||||||
| |||||||||||||||||||||||
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2024 | 15.4B | 15.2B | 15.0B | 14.7B |
| 2023 | 15.8B | 15.6B | 15.5B | 15.4B |
| 2022 | 17.6B | 17.2B | 16.7B | 16.3B |
| 2021 | 13.8B | 15.6B | 17.2B | 17.9B |
| 2020 | 11.6B | 11.7B | 11.8B | 11.9B |
| 2019 | 0 | 0 | 0 | 11.5B |
| 2018 | 0 | 0 | 0 | 11.4B |
Get all data in R, Python etc through our Historical Stock Data APIs
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
| CEO | Mr. Scott Andrew Smith |
|---|---|
| WEBSITE | viatris.com |
| SECTOR | Healthcare |
| INDUSTRY | Drug Manufacturers Specialty & Generic |
| EMPLOYEES | 38000 |
